Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended															12 Months Ended
		Dec. 31, 2019	[1]	Sep. 28, 2019	[2]	Jun. 29, 2019	[3]	Mar. 30, 2019	[3]	Dec. 31, 2018	Sep. 29, 2018	[4]	Jun. 30, 2018	[5]	Mar. 31, 2018	[6]	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Net sales		$ 1,322.8		$ 1,191.1		$ 1,149.0		$ 1,174.5		$ 1,195.2	$ 1,133.1		$ 1,186.4		$ 1,217.0		$ 4,837.4	[7]	$ 4,731.7	[7]	$ 4,946.2	[7]
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[8]																2,487.7		2,411.6		2,429.9
CSCA | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales	[8]																515.2		492.5		485.4
CSCA | Digestive health
Disaggregation of Revenue [Line Items]
Net sales	[8]																413.9		403.6		411.5
CSCA | Nutrition
Disaggregation of Revenue [Line Items]
Net sales	[8]																394.4		432.4		423.6
CSCA | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales	[8]																383.6		388.1		364.8
CSCA | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales	[8]																352.4		333.6		341.0
CSCA | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales	[8]																182.9		164.1		163.5
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	[8]																106.4		0.0		0.0
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[8]																43.7		93.9		141.3
CSCA | Vitamins, minerals and supplements
Disaggregation of Revenue [Line Items]
Net sales	[8]																28.6		26.1		38.0
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[9]																66.6		77.3		60.8
CSCI
Disaggregation of Revenue [Line Items]
Net sales																	1,382.2		1,399.3		1,406.2
CSCI | Upper respiratory
Disaggregation of Revenue [Line Items]
Net sales																	276.8		276.5		270.8
CSCI | Digestive health
Disaggregation of Revenue [Line Items]
Net sales																	27.1		29.5		29.2
CSCI | Pain and sleep-aids
Disaggregation of Revenue [Line Items]
Net sales																	167.9		170.0		150.8
CSCI | Healthy lifestyle
Disaggregation of Revenue [Line Items]
Net sales																	173.8		180.7		182.5
CSCI | Skincare and personal hygiene
Disaggregation of Revenue [Line Items]
Net sales																	371.6		396.5		401.8
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales																	51.2		8.9		11.0
CSCI | Vitamins, minerals and supplements
Disaggregation of Revenue [Line Items]
Net sales																	180.2		187.2		177.9
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[10]																133.6		150.0		182.2
RX
Disaggregation of Revenue [Line Items]
Net sales																	967.5		920.8		1,054.4
Other
Disaggregation of Revenue [Line Items]
Net sales																	$ 0.0		$ 0.0		$ 55.7

[1] Includes impairment charges of $141.6 million.   First
Quarter   Second
Quarter ⁽²⁾   Third
Quarter ⁽³⁾   Fourth
Quarter Year Ended December 31, 2018               Net sales $ 1,217.0
  $ 1,186.4
  $ 1,133.1
  $ 1,195.2
Gross profit $ 492.7
  $ 471.0
  $ 424.8
  $ 443.0
Change in financial assets $ 9.6
  $ (0.6 )   $ (74.9 )   $ (122.8 ) Net income (loss) $ 80.8
  $ 36.2
  $ (67.5 )   $ 81.5
Earnings (loss) per share⁽¹⁾:               Basic $ 0.57
  $ 0.26
  $ (0.49 )   $ 0.60
Diluted $ 0.57
  $ 0.26
  $ (0.49 )   $ 0.60
Weighted average shares outstanding:               Basic 140.8
  138.1
  137.4
  135.9
Diluted 141.4
  138.7
  137.4
  136.3

[2] ludes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.(4) Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.

[3] Includes change in financial assets of $10.4 million.

[4] Includes impairment charges of $221.8 million and restructuring charges and other termination benefits of $18.0 million.

[5] Includes acquisition-related charges and contingent consideration adjustments of $53.2 million.

[6] The sum of individual per share amounts may not equal due to rounding.

[7] The net sales by geography is derived from the location of the entity that sells to a third party.

[8] Includes net sales from our OTC contract manufacturing business.

[9] Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[10] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.